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ABSTRACT 78 
Talazoparib inhibits poly(ADP-ribose) polymerase (PARP) catalytic activity, trapping 79 
PARP1 on damaged DNA and causing cell death in BRCA1/2-mutated cells. We 80 
evaluated talazoparib therapy in this 2-part, phase I, first-in-human trial. Antitumor 81 
activity, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics 82 
of once-daily talazoparib were determined in an open-label, multicenter, dose-83 
escalation study (NCT01286987). The MTD was 1.0 mg/day, with an elimination 84 
half-life of 50 hours. Treatment-related adverse events included fatigue (26/71 85 
patients; 37%) and anemia (25/71 patients; 35%). Grade 3 to 4 adverse events 86 
included anemia (17/71 patients; 24%) and thrombocytopenia (13/71 patients; 18%). 87 
Sustained PARP inhibition was observed at doses ≥0.60 mg/day. At 1.0 mg/day, 88 
confirmed responses were observed in 7/14 (50%) and 5/12 (42%) patients with 89 
BRCA mutation-associated breast and ovarian cancers, respectively, and in patients 90 
with pancreatic and small cell lung cancer. Talazoparib demonstrated single-agent 91 
antitumor activity and was well tolerated in patients at the recommended dose of 1.0 92 
mg/day. 93 
 94 
SIGNIFICANCE: In this clinical trial, we show that talazoparib has single-agent 95 
antitumor activity and a tolerable safety profile. At its recommended phase II dose of 96 
1.0 mg/day, confirmed responses were observed in patients with BRCA mutation-97 
associated breast and ovarian cancers and in patients with pancreatic and small cell 98 
lung cancer.  99 
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INTRODUCTION 100 
The most studied poly(ADP-ribose) polymerase (PARP) enzymes are PARP1 and 2, 101 
which play critical roles in DNA damage detection and repair (1, 2), including the 102 
repair of single-strand DNA breaks through the base excision repair pathway (3–5). It 103 
has been hypothesized that single-strand DNA breaks persist when PARP function is 104 
compromised, leading to the creation of double-strand DNA breaks during replication 105 
(6); these double-strand DNA breaks are usually repaired by homologous 106 
recombination repair (HRR), allowing replication to continue (6). However, loss of 107 
PARP activity becomes lethal when HRR is compromised. This phenomenon, known 108 
as synthetic lethality, is well established for deleterious mutations of BRCA1 and 109 
BRCA2 (7–9).  110 
The PARP inhibitor, olaparib, was recently approved for the treatment of advanced 111 
ovarian cancer and remains the only approved agent. PARP inhibitors have also 112 
demonstrated antitumor activity against other tumor types with DNA repair 113 
deficiencies, including breast and prostate cancers (10–13). Talazoparib (also known 114 
as MDV3800, BMN 673) is a novel, potent, and selective inhibitor of PARP1/2 that 115 
achieves antitumor cell responses and elicits DNA repair markers at notably lower 116 
concentrations than earlier generation PARP1/2 inhibitors (14, 15). In addition to 117 
inhibiting PARP catalytic activity, talazoparib is currently the most potent PARP1/2 118 
inhibitor in vitro at trapping PARP-DNA complexes at sites of single-strand DNA 119 
breaks (16). Preclinically, talazoparib has favorable metabolic stability, oral 120 
bioavailability, and pharmacokinetics (PK) that support its daily schedule in clinical 121 
trials (14).  122 
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We conducted a first-in-human, phase I dose escalation (Part 1) trial of talazoparib in 123 
patients with advanced solid malignancies and an expansion cohort (Part 2) in 124 
patients with tumors predicted to be potentially sensitive to PARP inhibition. These 125 
included: tumors harboring germline BRCA1/2 mutations; triple-negative breast 126 
cancers; high-grade serous and/or undifferentiated ovarian, fallopian tube, or 127 
peritoneal cancers; and castration-resistant prostate and pancreatic cancers. 128 
Ewing’s sarcoma and small cell lung cancer (SCLC) patients were also studied; the 129 
former was based on a 1000-cell line screen demonstrating antitumor activity (17, 130 
18), and the latter was based on SCLC platinum sensitivity, increased PARP1 131 
expression, and sensitivity of SCLC cell lines and animal models to PARP inhibition 132 
(19, 20).  133 
 134 
 135 
RESULTS 136 
Between January 3, 2011, and August 21, 2014, 113 patients with advanced solid 137 
tumors were enrolled at a total of six centers: five in the United States and one in the 138 
United Kingdom. A total of 110 patients received talazoparib (Table 1). Thirty-nine 139 
patients participated in Part 1 and received talazoparib at nine dose levels ranging 140 
from 0.025 to 1.1 mg/day (Fig. 1). An additional 71 patients were treated with 141 
talazoparib 1.0 mg/day in Part 2. As of the date of database cutoff (March 31, 2015), 142 
two patients in Part 1 and five patients in Part 2 continue to be treated (Fig. 1).  143 
Safety 144 
The number of patients per dose level, observed dose-limiting toxicities (DLTs), dose 145 
reductions, and median time on study are provided in Table 2. Dose-limiting 146 
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thrombocytopenia in cycle 1 occurred in one of six patients at 0.9 mg/day and two of 147 
six patients assessable for DLT at 1.1 mg/day. The patient treated at 0.9 mg/day 148 
experienced grade 3 thrombocytopenia with grade 3 anemia. Of the two patients 149 
treated at 1.1 mg/day, both experienced grade 3 thrombocytopenia; for one of these 150 
patients it became grade 4 thrombocytopenia. All DLTs resolved after temporary 151 
interruption of study drug; no hemorrhage was noted. As two patients experienced a 152 
DLT at the 1.1 mg/day dose level, an interim dose of 1.0 mg/day was investigated. 153 
No DLTs were observed at this dose level in a group of six assessable patients. This 154 
dose was therefore determined to be the maximum tolerated dose (MTD) and the 155 
recommended dose for Part 2. 156 
In Part 2, 71 patients received talazoparib at 1.0 mg/day via continuous daily dosing. 157 
The median relative dose intensity was high at 97.2% and the dose was well 158 
tolerated. Table 2 presents the most common toxicities at this dose related to the 159 
study drug, including fatigue (37%), anemia (35%), nausea (32%), thrombocytopenia 160 
(21%), alopecia (20%), and neutropenia (15%). Grade 3 or 4 adverse events (AEs) 161 
assessed by investigator as related were reported in 32 (45%) patients, with the 162 
most frequent being anemia (23%), thrombocytopenia (18%), and neutropenia 163 
(10%).   164 
Of the 77 patients receiving the 1 mg/day dose, 26 patients (34%) reported at least 165 
one dose reduction, the majority of whom (20 patients) had reductions due to an AE 166 
such as anemia, thrombocytopenia, and neutropenia. Although transient dose 167 
holidays were needed as a result of these AEs, no patients permanently withdrew 168 
from treatment because of them in either Part 1 or Part 2 of the trial. 169 
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There were eight deaths associated with an AE during the study, none of which were 170 
considered to be related to study treatment. Two of the deaths occurred in patients 171 
with breast cancer enrolled in Part 1 at the entry dose of 1.1 mg/day talazoparib 172 
(both related to disease progression). Six of the deaths occurred in patients in Part 2 173 
at 1.0 mg/day talazoparib (two patients with pancreatic cancer, both from disease 174 
progression; two patients with Ewing’s sarcoma, one from dyspnea and the other 175 
from respiratory failure; and two patients with SCLC, one from hypoxia secondary to 176 
lung metastases and the other from lung infection). 177 
Pharmacokinetics 178 
Mean talazoparib plasma concentration-time profiles following single and multiple 179 
doses of talazoparib are provided in Fig. 2 A-D. Talazoparib PK parameters resulting 180 
from the analysis of the plasma concentration-time profiles are provided in Table 3. 181 
Talazoparib demonstrated rapid absorption, with maximum plasma concentration 182 
(Cmax) generally reached within 2 hours after all evaluated doses and following both 183 
single and multiple daily dosing. Steady-state plasma concentrations were reached 184 
by 2 weeks of daily dosing across all doses evaluated. Talazoparib was well 185 
distributed into tissue compartments, with apparent volume of distribution (Vz/F) 186 
estimates well in excess of the volume of the systemic circulatory space. Plasma 187 
elimination followed biphasic kinetics with a long terminal half-life (t1/2). Linear 188 
elimination across dose levels was apparent following both single and multiple daily 189 
dosing as evidenced by parallel terminal phases of the log-linear profiles and similar 190 
apparent oral clearance (CL/F) estimates across dose levels. At the MTD dose of 1.0 191 
mg/day, t1/2 is approximately 2 days and mean accumulation ratio is 2.4-fold at 192 
steady-state. 193 
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Plasma concentrations, Cmax, and area under the plasma concentration-time curve 194 
(AUC) estimates increased approximately with doses ranging from 0.025 to 1.1 mg 195 
following multiple daily dosing as shown in Fig. 2 E-H. Estimates (95% confidence 196 
interval [CI]) of the dose proportionality parameter, β, for Cmax and AUC from 0 to 24 197 
hours (AUC0-24) following multiple daily doses of talazoparib were 1.11 (1.01–1.20) 198 
and 0.95 (0.84–1.05), respectively.  199 
Results for urinary elimination of the parent compound suggest linear urinary 200 
elimination kinetics after daily talazoparib dosing between the 0.025 and 1.1 mg 201 
dose levels. Following single doses in Part 1, mean values for the amount of the 202 
analyte excreted in urine from 0 to 24 hours (Ae0-24) and the fraction of urine 203 
excretion from 0 to 24 hours (Fe0-24) generally increased with dose, and average 204 
renal clearance from time 0 to 24 hours postdose (ARC0-24) values were similar 205 
across dose levels. Following multiple daily doses in Part 1, Ae0-24 increased with 206 
increasing dose, whereas mean Fe0-24 and ARC0-24 values were generally similar 207 
across the 0.025 and 1.1 mg/day dose levels. 208 
Pharmacodynamics 209 
The mean percentage baseline peripheral blood mononuclear cell (PBMC) PARP 210 
activities with multiple-dose talazoparib by dose level are provided in Table 3 and 211 
Supplementary Fig. S1. Overall, PBMC PARP activity decreased with talazoparib 212 
dose across the evaluated dose range.   213 
The dose- and concentration-response relationships between talazoparib and PBMC 214 
PARP activity are shown in Fig. 2 E-H, and maximum inhibitory effect model 215 
parameter estimates are provided in Supplementary Table S1. In the exposure-216 
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response curve, an estimated half maximal inhibitory concentration of AUC0-24 was 217 
19,000 pg.h/mL. 218 
Efficacy 219 
In 14 patients with breast cancer (all with deleterious BRCA1/2 mutations) treated 220 
with talazoparib at 1.0 mg/day, the objective response rate (ORR) was 50% and 221 
included one complete response (CR; Table 4). Five patients had stable disease 222 
(SD) lasting at least 24 weeks, resulting in a clinical benefit rate (CBR) of 86% for at 223 
least 24 weeks. Median progression-free survival (PFS) was 34.6 weeks (95% CI, 224 
27.1–54.0) (Table 4). For the total of 18 patients with breast cancer with deleterious 225 
BRCA1/BRCA2 mutations treated at any talazoparib dose level, the ORR and CBR 226 
were higher in patients whose tumors carried the BRCA2 mutation (ORR, 55%, 6/11 227 
patients; CBR, 91%, 10/11 patients) compared with those who had the BRCA1 228 
mutation (ORR, 38%, 3/8 patients; CBR, 50%, 4/8 patients; percentage change in 229 
target lesion size summarized in Fig. 3A). Of note, one patient had aberrations in 230 
both BRCA1 and BRCA2, although the BRCA2 aberration detected may not be 231 
deleterious (Y3098X). Interestingly, in the BRCA-mutated breast cancer patients, 232 
higher antitumor activity was observed in patients with non–triple-negative breast 233 
cancer (n = 9) than in those with triple-negative disease (n = 9) (CBR, 89% vs. 56% 234 
≥24 weeks; median PFS, 38.3 weeks [95% CI, 2.6–67.4] vs. 20.4 weeks [95% CI, 235 
3.1–36.1]). Six of the 18 BRCA-mutated breast cancer patients had received prior 236 
platinum therapy, of whom two had an objective response. 237 
In 12 patients with ovarian cancer with deleterious germline BRCA1/2 mutations with 238 
measurable disease treated with talazoparib 1.0 mg/day, ORR and CBR lasting at 239 
least 24 weeks equaled 42% and 67%, respectively, with a median PFS of 36.4 240 
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weeks (Table 4). For all patients with BRCA-mutated ovarian cancer treated at any 241 
talazoparib dose level with measurable disease (n = 25), ORR and CBR lasting at 242 
least 24 weeks was 48% (including one CR) and 76%, respectively (percentage 243 
change in target lesion size is summarized in Fig. 3B). All 25 patients had received 244 
prior platinum-based chemotherapy; the ORR in platinum-sensitive patients was 245 
55% (11/20 patients) compared with 20% (1/5 patients) in platinum-resistant 246 
patients.  247 
All 23 SCLC patients were enrolled in Part 2 and treated with 1.0 mg/day. Median 248 
number of prior regimens was 1, ranging from 0 to 2. Two patients had a partial 249 
response (PR) (ORR, 9%, with duration of response, 12.0 and 15.3 weeks, 250 
respectively), and a further four had SD lasting at least 16 weeks (CBR, 26% ≥16 251 
weeks; Table 4). For the two patients with an objective response, both had had an 252 
objective response to the last prior platinum therapy, with a platinum-free interval of 253 
6 months or less. Median PFS for this group was 11.1 weeks (95% CI, 4.3–13.0). 254 
Of the 13 patients with pancreatic cancer from Part 1 and Part 2, four had clinical 255 
benefit (CBR, 31% ≥16 weeks): two patients had a PR, one with BRCA2 mutation, 256 
the other with a PALB2 mutation (Table 4). For patients with Ewing’s sarcoma, no 257 
objective response was observed, and the CBR (SD ≥16 weeks) was 23%. 258 
For the seven patients currently receiving talazoparib on the study as of the data 259 
cutoff of March 31, 2015, four have ovarian cancer (continuing on study for 27.4, 260 
28.1, 31.5, and 36.6 months, and one patient each has breast, pancreatic, and 261 
prostate cancer (24.2, 22.8, and 8.4 months, respectively). The starting dose for 262 
these patients ranged between 0.9 and 1.0 mg/day; current dose is between 0.5 and 263 
1.0 mg/day.   264 
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 265 
DISCUSSION 266 
Talazoparib is a potent oral PARP1/2 inhibitor that has equivalent catalytic activity to 267 
olaparib and rucaparib, but is superior in trapping PARP-DNA at the site of DNA 268 
damage by comparison (16). This first-in-human study demonstrated that talazoparib 269 
results in single-agent activity in patients harboring germline deleterious BRCA 270 
mutations or whose tumors harbor other mutations sensitive to PARP inhibition. The 271 
clinical activity observed with talazoparib suggests that targeting of PARP1/2 may 272 
also be an effective strategy for those patients whose tumors harbor other genomic 273 
abnormalities involved in DNA repair mechanisms (13). 274 
Talazoparib was well tolerated overall. The primary toxicity of talazoparib was 275 
hematological, with transient and reversible cytopenias (thrombocytopenia, 276 
neutropenia, and anemia), primarily managed with drug interruption and/or dose 277 
reduction and otherwise routine medical intervention; transfusions were uncommon. 278 
All episodes of DLT involved brief thrombocytopenia without hemorrhage. 279 
Nonhematological toxic effects were mild in severity and manageable. The relative 280 
dose intensity was high at 97.2% and overall the dose was well tolerated. 281 
Furthermore, no patients permanently withdrew from talazoparib treatment because 282 
of toxicity, in either Part 1 or 2 of this study. 283 
Talazoparib demonstrated favorable PK properties with good oral bioavailability, 284 
rapid absorption, and dose proportional increases in total exposure (AUC) over a 285 
wide dose range (0.025–1.1 mg/day). Steady-state was reached approximately 2 286 
weeks after initiation of daily dosing. Linear urinary elimination kinetics were reported 287 
with daily dosing. At the recommended phase 2 dose of 1.0 mg/day, the terminal 288 
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half-life was approximately 2 days upon multiple dosing; trough talazoparib plasma 289 
concentrations were maintained above 10 nM, suggesting that systemic 290 
concentrations of talazoparib are sufficient to inhibit PARP activity.   291 
In pharmacodynamic (PD) testing, talazoparib demonstrated PARP inhibition in 292 
PBMCs over a relatively wide range of doses. For doses at and above 0.6 mg/day, 293 
PARP activity was consistently inhibited in all patients evaluated. Pharmacodynamic 294 
results suggest that effective PARP inhibition could still be achieved at reduced dose 295 
levels.    296 
Talazoparib demonstrated promising antitumor activity in patients with heavily 297 
pretreated breast and ovarian cancers associated with deleterious germline 298 
BRCA1/2 mutations. Single-agent activity in patients with advanced breast cancer 299 
(including patients with triple-negative disease) equaled 50% (ORR) and 86% (CBR). 300 
Similarly, in the 12 BRCA-mutated ovarian cancer patients treated with 1.0 mg/day of 301 
talazoparib, ORR and CBR equaled 42% and 67%, respectively.   302 
Of note, one responding patient with pancreatic cancer harbored a PALB2 mutation 303 
(21); as this mutation is known to recruit BRCA2 and RAD51 to DNA breaks, such 304 
findings support a trial in a broader population (those with additional DNA repair 305 
deficiencies as opposed to BRCA mutations only), potentially expanding applications 306 
for PARP inhibitor therapy.  307 
In conclusion, the findings from this study demonstrate the effectiveness of single-308 
agent talazoparib for treatment of patients with and without germline BRCA1/2 309 
mutations in ovarian, breast, small cell lung, and pancreatic cancers. Talazoparib 310 
has a tolerable safety profile in multiple patients seen over a treatment period 311 
exceeding 2 years. The PK properties of talazoparib support once-daily dosing. Data 312 
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from this phase 1 trial supports a role for talazoparib in treatment of patients with 313 
advanced tumors (inherited and sporadic cancers with DNA repair deficiencies). 314 
Talazoparib is currently undergoing further clinical investigation against multiple 315 
tumor types, including a phase 3 trial in patients with metastatic breast cancer with a 316 
deleterious BRCA1/2 mutation.  317 
 318 
METHODS 319 
Study Design and Participants 320 
We undertook a phase I study of talazoparib in patients with advanced solid tumors 321 
and either germline BRCA1/2 mutations or a strong preclinical rationale for use of a 322 
PARP inhibitor. Eligible patients were aged 18 years or older and had: histologically 323 
or cytologically documented unresectable, locally advanced, or metastatic solid 324 
tumors not suitable for established therapy or for which standard therapy had failed; 325 
Eastern Cooperative Oncology Group Performance Status of 0 or 1; and adequate 326 
hematological and liver function. 327 
Patients enrolled in Part 1 (dose escalation) had tumors known to harbor DNA repair 328 
deficiencies (Supplementary Methods); provision of documentation (genomic or 329 
immunohistochemistry) was not required. Enrollment in Part 2 was restricted to 330 
patients with selected tumors with confirmed BRCA1/2 germline pathogenic or 331 
deleterious mutations by BRACAnalysis® (Myriad Genetics, Salt Lake City, Utah) or 332 
local laboratory evaluation (ovarian or peritoneal, breast, prostate, or pancreatic 333 
cancers), patients with DNA repair deficiency, or patients with SCLC or Ewing’s 334 
sarcoma (Supplementary Methods). Patient eligibility, including a full list of exclusion 335 
criteria is provided in the Supplementary Methods.  336 
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The study was conducted in accordance with the protocol, good clinical practice 337 
standards, and the Declaration of Helsinki and the International Conference on 338 
Harmonisation. The appropriate institutional review board or ethics committee at 339 
each participating institution approved the protocol. All enrolled patients provided 340 
written informed consent before undergoing study specific procedures. 341 
Study Treatment  342 
For Part 1, fasted patients received a single dose of talazoparib at the start of the 343 
study and then underwent PK and PD assessments 1 week later. Following 344 
assessments, patients received talazoparib once daily, continuously for 28-days, 345 
again followed by a 1-week break from treatment (defined as cycle 1) to assess PK 346 
and PD. Dosing was continuous thereafter without breaks except as needed for 347 
toxicity. A standard 3+3 design was used for dose escalation (22), with a starting 348 
talazoparib dose of 0.025 mg/day. Dose doubling occurred provided toxicities were 349 
Common Terminology Criteria for Adverse Events grade 1 or less during cycle 1; 350 
dose escalations were limited to 25%–50% once grade 2 drug-related toxicities were 351 
observed (25% for grade 3 drug-related toxicity). For each cohort, the first patient 352 
was observed for 15 days prior to additional patient enrollment. To be eligible for 353 
DLT assessment, a patient must have received at least 24 of the planned 28 doses 354 
of talazoparib between days 8 and 35. A DLT was defined as any of the following 355 
events occurring during cycle 1: grade 4 neutropenia associated with grade 2 or 356 
greater infection or lasting at least 5 days; grade 4 thrombocytopenia (or grade 3 357 
with either hemorrhage or dose interruption for ≥5 days); any AE of grade 3 or 358 
greater considered related to talazoparib, except a nonhematologic asymptomatic 359 
grade 3 laboratory AE, grade 3 nausea, vomiting, and/or diarrhea medically 360 
managed to grade 2 or less within 24 hours, or grade 3 fatigue that improved to 361 
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grade 2 or less in no more than 5 days (additional information provided in the 362 
Supplementary Methods).  363 
Enrollment in Part 2 proceeded once the MTD was determined. Patients received 364 
talazoparib at the MTD of 1.0 mg/day starting from cycle 1, day 1 (28-day cycles). 365 
Participation in the study could be discontinued at any time at the discretion of the 366 
investigator and in accordance with clinical judgment. 367 
Adverse events were recorded from the time of first dose of talazoparib until 30 days 368 
after the last dose. 369 
Study Procedures 370 
At screening, patients underwent physical examination (with vital signs and 371 
performance status assessment). Safety laboratory tests (complete blood count with 372 
differential and platelets, chemistry) were obtained weekly; coagulation and 373 
urinalysis were obtained weekly (cycle 1) and at the beginning of each cycle 374 
thereafter. Hematology evaluations were conducted more frequently upon 375 
observation of grade 2 or greater neutropenia or thrombocytopenia. Further details of 376 
study procedures are given in the Supplementary Methods. 377 
Pharmacokinetic Analysis 378 
Plasma and urine samples were assayed for talazoparib concentrations using a 379 
validated high-performance liquid chromatography with tandem mass spectrometry 380 
detection method. For plasma, the lower limit of quantitation (LLOQ) was 5.0 pg/mL; 381 
for urine, the LLOQ was 25.0 pg/mL. Talazoparib PK parameters (following single 382 
and multiple daily dosing) were obtained using standard noncompartmental analysis 383 
methods in Phoenix® WinNonlin® Version 6.4 (Certara L.P., Princeton, New Jersey). 384 
Pharmacokinetic parameters estimated included: Cmax; time to Cmax; AUC0-24, AUC 385 
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from time 0 to time of last quantifiable concentration, and AUC from time 0 386 
extrapolated to infinity; CL/F; Vz/F; and t1/2. The multiple-dose PK parameters also 387 
estimated included minimum plasma concentration and CL/F at steady-state. Dose 388 
proportionality following single and multiple daily dosing of talazoparib was assessed 389 
using a power model approach (23).   390 
Pharmacodynamic Analysis 391 
See the Supplementary Methods for details.  392 
Statistical Analysis 393 
The primary objective in Part 1 of this study was to determine the MTD and 394 
recommended dose of daily oral talazoparib; secondary objectives included safety, 395 
PK, and PD profiles. For Part 2, efficacy parameters in the selected tumor types 396 
were investigated per a prespecified analysis based on Response Evaluation Criteria 397 
In Solid Tumors version 1.1 through investigator assessment of lesion 398 
measurements, including ORR (in patients with measurable disease) or disease-399 
specific changes in tumor markers using standard definitions (24–26). The number 400 
and percentage of patients achieving a response were summarized with an exact 401 
95% CI calculated using the Clopper-Pearson method. The PFS was summarized 402 
using the Kaplan-Meier method. The data cutoff was March 31, 2015. SAS® 403 
Analytics Software (version 9.1; SAS Institute, Inc., Cary, North Carolina) was used 404 
for data analyses. 405 
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TABLES 504 
Table 1. Demographics and baseline clinical characteristics 505 
Demographic parameter 
Dose escalation (part 1)
(n = 39) 
Dose expansion (part 2) 
(n = 71) 
Overall  
(N = 110) 
Median age, years (range) 58.0 (19–81) 57.0 (18–88) 57.0 (18–88) 
Male, n (%) 6 (15.4) 28 (39.4) 34 (30.9) 
ECOG Performance Status, n (%)    
0 23 (59.0) 37 (52.1) 60 (54.5) 
1 16 (41.0) 34 (47.9) 50 (45.5) 
Tumor type, n (%)    
Breast 8 (20.5) 12 (16.9) 20 (18.2) 
Ovarian/peritoneal 23 (59.0) 11 (15.5) 34 (30.9) 
Prostate 1 (2.6) 3 (4.2) 4 (3.6) 
Pancreatic 3 (7.7) 10 (14.1) 13 (11.8) 
Ewing’s sarcoma 2 (5.1) 12 (16.9) 14 (12.7) 
Small cell lung cancer 0 23 (32.4) 23 (20.9) 
Colorectal cancer 2 (5.1) 0 2 (1.8) 
Deleterious mutation, n (%)    
gBRCA1 16 (41.0) 13 (18.3) 29 (26.4) 
gBRCA2 7 (17.9) 20 (28.2) 27 (24.5) 
gBRCA1/2 1 (2.6) 2 (2.8) 3 (2.7) 
Median prior chemotherapy 
regimens, n (range) 
4.0 (1.0–13.0) 2.0 (0.0–6.0) 2.5 (0.0–13.0) 
Median prior platinum regimens, 
n (range) 
2.0 (0.0–4.0) 1.0 (0.0–4.0) 1.0 (0.0–4.0) 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; gBRCA, germline BRCA mutated. 
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Table 2. Part 1 dose escalation schema, DLTs, dose reductions, and common 508 
adverse events (>15%) or grade 3–4 adverse event (>4%) assessed by investigator 509 
as related at the recommended dose 510 
Dose 
level 
Patients 
(n = 39) 
DLTs in first cycle Dose reductions 
(any cycle) 
Number of 
treatment days  
Number Description Number Median (range)
0.025 mg 3 0 - 2 35 (35–98) 
0.05 mg 3 0 - 2 99 (34–205) 
0.10 mg 3 0 - 2 119 (65– 253) 
0.20 mg 3 0 - 2 281 (35 –427) 
0.40 mg 3 0 - 1 226 (97–268) 
0.60 mg 6 0 - 4 185 (58–289) 
0.90 mg 6 1 Grade 3 TCP 5 261 (30–1114) 
1.00 mg 6 0 - 5 214 (84–960) 
1.10 mg 6a 2 Grade 3–4 TCP 4 60 (14–196) 
Adverse event All grade
(n = 71) 
Grade 3-4 
(n = 71) 
Any treatment-emergent adverse event, n (%) 55 (77) 32 (45) 
Blood and lymphatic system disorders, n (%) 40 (56) 30 (42) 
Anemia 25 (35) 16 (23) 
TCP 15 (21) 13 (18) 
Neutropenia 11 (15) 7 (10) 
Gastrointestinal disorders, n (%) 27 (38) - 
Nausea 23 (32) - 
General disorders and administration site conditions, 
n (%) 
27 (38) 2 (3) 
Fatigue 26 (37) 2 (3) 
Skin and subcutaneous tissue disorders, n (%) 19 (27) - 
Alopecia 14 (20) - 
Abbreviations: DLT, dose-limiting toxicity; TCP, thrombocytopenia.  
aOne patient discontinued from the trial on study day 21 for progressive disease, having received 
only 8 days of continuous dosing.  
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Table 3. Pharmacokinetic parameters and PARP inhibition following single and multiple daily dosing 513 
PK parameter 
Single talazoparib dose, mg 
0.025 
(n = 3) 
0.05 
(n = 3) 
0.1 
(n = 3) 
0.2 
(n = 3) 
0.4 
(n = 3) 
0.6 
(n = 6)a 
0.9 
(n = 6)b 
1.0 
(n = 5) 
1.1 
(n = 7)c 
Tmax, median (min, 
max), h 
7.92 
(1.95, 9.95) 
1.00 
(0.80, 1.02)
1.02 
(1.00, 3.98)
1.03 
(1.00, 2.32)
2.03 
(0.75, 2.95)
0.835 
(0.75, 1.95)
2.00 
(1.02, 9.98)
1.03 
(0.73, 2.07)
1.00 
(0.73, 2.05) 
Cmax, mean (SD), pg/mL 60.0 
(15.9) 
79.7 
(7.50) 
214 
(50.9) 
788 
(369) 
1,830 
(699) 
4,100 
(1,400) 
6,100 
(3,060) 
10,600 
(4,220) 
13,200 
(3,220) 
AUC0-24, mean (SD), 
pg·h/mL 
952 
(386) 
1,160 
(166) 
3,160 
(1,270) 
9,130 
(3,540) 
13,500 
(5,200) 
37,900 
(12,900) 
58,200 
(24,300) 
85,100 
(29,100) 
91,600 
(31,800) 
AUC0-t, mean (SD), 
pg·h/mL 
3,600 
(1,360) 
5,340 
(1,960) 
16,600 
(5320) 
39,300 
(11,700) 
43,700 
(15,000) 
97,900 
(30,000) 
160,000 
(66,100) 
182,000 
(62,400) 
201,000 
(93,400) 
AUC0-∞, mean (SD), 
pg·h/mL 
5,330 
(1,840) 
8,320 
(1,960) 
37,600 
(6,620) 
92,700 
(48,500) 
60,100 
(15,900) 
120,000 
(26,000) 
188,000 
(85,700) 
200,000 
(64,000) 
235,000 
(111,000) 
t1/2, mean (SD), h 100 
(11.9) 
129 
(42.6) 
229 
(158) 
212 
(126) 
102 
(27.2) 
58.6 
(17.3) 
60.4 
(10.9) 
52.9 
(13.4) 
71.0 
(20.6) 
CL/F, mean (SD), L/h 5.17 
(2.10) 
6.27 
(1.66) 
2.72 
(0.532) 
2.61 
(1.35) 
6.95 
(1.71) 
5.19 
(0.99) 
5.49 
(2.08) 
5.39 
(1.59) 
5.32 
(1.64) 
Vz/F, mean (SD), L 756 
(351) 
1240 
(742) 
839 
(487) 
678 
(217) 
1050 
(431) 
441 
(143) 
468 
(169) 
415 
(170) 
549 
(232) 
 Multiple daily talazoparib dosing, mg/day 
 0.025 
(n = 3)d,e 
0.05 
(n = 2) 
0.1 
(n = 2)f 
0.2 
(n = 3) 
0.4 
(n = 3) 
0.6 
(n = 6)g 
0.9 
(n = 5)h 
1.0 
(n = 6) 
1.1 
(n = 4)i 
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Tmax, median (min, 
max), h 
1.02 
(0.58, 3.98) 
5.43 
(0.77, 10.1)
0.76 
(0.75, 0.82)
1.97 
(1.00, 3.02)
0.98 
(0.75, 2.00)
1.04 
(0.73, 5.98)
1.02 
(0.97, 2.07)
1.02 
(0.75, 2.00)
1.48 
(0.98, 2.00) 
Cmax, mean (SD), pg/mL 300 
(78.8) 
615 
(74.2) 
1,880 
(332) 
5,620 
(3,530) 
6,560 
(1,500) 
11,300 
(3,230) 
15,400 
(1,540) 
21,000 
(7,990) 
23,400 
(4,810) 
AUC0-24, mean (SD), 
pg·h/mL 
3,960 
(759) 
9,770 
(2,440) 
30,000 
(4,490) 
83,100 
(49,300) 
67,300 
(22,600) 
119,000 
(19,900) 
157,000 
(24,500) 
202,000 
(54,000) 
188,000 
(29,200) 
t1/2, mean (SD), h 107 
(84.2) 
132 
(12.3) 
98.2 
(4.83) 
50.9 
(19.1) 
90.7 
(32.7) 
63.7 
(12.7) 
71.0 
(14.5) 
50.0 
(16.6) 
52.8 
(23.2) 
CLss/F, mean (SD), L/h 6.43 
(1.23) 
5.28 
(1.32) 
3.37 
(0.502) 
3.12 
(1.91) 
6.40 
(2.07) 
5.15 
(0.897) 
5.86 
(0.951) 
5.24 
(1.39) 
5.96 
(0.837) 
Vz/F, mean (SD), L 1,070 
(971) 
1,020 
(345) 
475 
(47.8) 
264 
(249) 
818 
(326) 
477 
(136) 
604 
(169) 
373 
(144) 
472 
(254) 
Cmin, mean (SD), pg/mL 169 
(58.0) 
299 
(133) 
1,020 
(107) 
2,880 
(1,710) 
2,230 
(957) 
3,470 
(1,050) 
3,180 
(802) 
3,720 
(1,590) 
2,910 
(803) 
 PARP activity, % baseline 
 0.025 
(n = 3) 
0.05 
(n = 3) 
0.1 
(n = 3) 
0.2 
(n = 3) 
0.4 
(n = 3) 
0.6 
(n = 4) 
0.9 
(n = 4) 
1.0 
(n = 4) 
1.1 
(n = 2) 
PARP activity, mean 
(SD) 
172  
(206) 
141  
(52.5) 
102  
(98.0) 
14.7  
(5.04) 
111  
(96.5) 
24.7  
(8.19) 
34.7  
(27.4) 
21.1  
(14.9) 
16.3  
(5.63) 
Abbreviations: AUC0-24, area under the plasma concentration-time curve (AUC) from 0 to 24 h; AUC0-∞, AUC from time 0 extrapolated to infinity; 
AUC0-t, AUC from time 0 to last quantifiable concentration; CL/F, apparent oral clearance; CLss/F, CL/F at steady-state; Cmax, maximum plasma 
concentration; PARP, poly(ADP-ribose) polymerase; PK, pharmacokinetics; SD, standard deviation; t1/2, terminal half-life; Tmax, time to Cmax; Vz/F, 
apparent volume of distribution. 
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Table 4. Clinical response rate (RECIST) by cancer type in patients treated with 515 
talazoparib 1.0 mg/day (recommended phase 2 dose) 516 
Response 
Breasta 
(n = 14) 
Ovarian/ 
peritoneala 
(n = 12) 
SCLC  
(n = 23) 
Pancreatic  
(n = 10) 
Ewing’s 
sarcoma  
(n = 13) 
ORR,%  50.0 41.7 8.7 20.0 0 
CR, n 1 1 0 0 0 
PR, n 6 4 2 2 0 
 SD, n 5b 3b 4c 1c 3c 
CBR,%b,d 85.7 66.7 26.1 30.0 23.1 
Median PFS, weeks 34.6 36.4§ 11.1 ND ND 
Abbreviations: CBR, clinical benefit rate; CR, complete response; ND, not determined; ORR, objective 
response rate; PFS, progression-free survival; PR, partial response; RECIST, Response Evaluation 
Criteria In Solid Tumors; SCLC, small cell lung cancer; SD, stable disease. 
aPatients had BRCA1/2 mutation. 
bClinical benefit = CR + PR + SD ≥24 weeks for breast and ovarian cancers. 
cAnalysis on 14 patients, as two patients who did not have measurable disease at baseline were 
included in the PFS analysis but not in the response analysis. 
dClinical benefit = CR + PR + SD ≥16 weeks for SCLC, pancreatic cancer, Ewing’s sarcoma. 
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FIGURE LEGENDS 520 
Figure 1. Patient enrollment and disposition. Abbreviation: ECOG, Eastern 521 
Cooperative Oncology Group. 522 
 523 
Figure 2. Pharmacokinetic and pharmacodynamic features of talazoparib.  524 
A-D, mean concentration-time profiles of talazoparib. Linear mean talazoparib 525 
plasma concentration-time profiles over the initial 24 hours postdose and log-linear 526 
mean talazoparib plasma concentration-time profilers over the complete sampling 527 
interval following: A, B, single doses of talazoparib; C, D, multiple daily doses of 528 
talazoparib. E-H, dose proportionality of talazoparib pharmacokinetics and dose-529 
response and exposure-response relationships between talazoparib and PBMC 530 
PARP activity. E, plasma Cmax following multiple daily doses ranging from 0.025 to 531 
1.1 mg. F, AUC0-24 following multiple daily doses ranging from 0.025 to 1.1 mg. Filled 532 
circles represent the mean value at each dose level and error bars represent the 533 
standard deviations. Solid line represents the power model fit through the data. G, 534 
dose-response relationship between talazoparib and PBMC PARP activity. H, 535 
exposure-response relationship between talazoparib and PBMC PARP activity. 536 
Percentage baseline PBMC PARP activity defined as the mean of the predose 537 
PARP activity assessments during the multiple dosing assessment phase (i.e., 538 
predose assessments on days 15, 22, and 35 of cycle 1). Abbreviations: AUC0-24, 539 
area under the plasma concentration-time curve from 0 to 24 h; Cmax, maximum 540 
plasma concentration; IC50, half maximal inhibitory concentration; ID50, inhibitory 541 
dose 50%; PARP, poly(ADP-ribose) polymerase; PBMC, peripheral blood 542 
mononuclear cells.  543 
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 544 
Figure 3. Percentage change in target lesion for patients undergoing treatment with 545 
talazoparib who have: A, gBRCA breast cancer; B, gBRCA ovarian cancer. Positive 546 
values indicate tumor growth, negative values indicate tumor reduction, and the 547 
dashed line represents the definition of partial response from Response Evaluation 548 
Criteria In Solid Tumors guidelines. Abbreviations: gBRCA, germline BRCA mutated; 549 
SLD, sum of longest diameter. 550 
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Part 1
Dose Escalation Phase
Part 2
Dose Expansion Phase
39 patients screened and enrolled
• 3 received 0.025 mg/day
• 3 received 0.05 mg/day
• 3 received 0.1 mg/day
• 3 received 0.2 mg/day
• 3 received 0.4 mg/day
• 6 received 0.6 mg/day
• 6 received 0.9 mg/day
• 6 received 1.0 mg/day
• 6 received 1.1 mg/day
37 patients discontinued
• 28 with disease progression
• 8 with clinical progression
• 1 by physician decision
71 patients enrolled and received 1.0 mg/day
• 12 patients with breast cancer
• 11 patients with ovarian/peritoneal cancer
• 3 patients with prostate cancer
• 10 patients with pancreatic cancer
• 12 patients with Ewing’s sarcoma
• 23 patients with small cell lung cancer
66 patients discontinued
• 56 with disease progression
• 6 with clinical progression
• 2 withdrew from study
• 2 died
5 patients continuing treatment
3 patients ineligible 
because ECOG PS
74 patients screened
2 patients continuing treatment
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